Artivion Reports 18% Revenue Growth to $116.3 Million in Q1 2026

Artivion, Inc. reported a significant increase in financial performance for the first quarter of 2026, with total revenues reaching $116.3 million, an 18% rise compared to $98.98 million in the same period of 2025. The growth was driven by higher sales in aortic stent grafts, preservation services, On-X products, and surgical sealants. Notably, revenues from aortic stent grafts alone increased by 21%, while preservation services saw a 23% increase. The company also noted that constant currency revenues, which adjust for foreign exchange effects, increased by 12% year-over-year.

The company's gross margin improved to $75.4 million, up 19% from $63.6 million in the prior year, reflecting a gross margin percentage of 65% of total revenues. This increase was attributed to a favorable product mix, higher average sales prices, and increased sales volume, although it was partially offset by rising costs for certain products. Operating income also saw a notable increase, reaching $5.8 million compared to $2.1 million in the previous year, while net income turned positive at $1.4 million, a recovery from a net loss of $0.5 million in Q1 2025.

In terms of strategic developments, Artivion has made significant moves in its operational landscape. The company has continued its partnership with Baxter International, manufacturing and supplying PerClot, a hemostatic agent, which contributed $0.6 million in revenue during the quarter. Additionally, Artivion is in the process of acquiring Endospan, with plans to utilize $135 million from a new delayed draw term loan facility to fund the acquisition. This acquisition is expected to enhance Artivion's product offerings in the aortic arch repair market.

Operationally, Artivion reported a slight increase in employee headcount, with 48,074 basic shares outstanding as of March 31, 2026, compared to 42,232 a year earlier. The company also maintained a strong liquidity position, with cash and cash equivalents totaling $55.8 million and access to $30 million under its revolving credit facility. However, cash flows from operating activities showed a modest increase to $1.2 million, a significant improvement from a cash outflow of $17 million in the previous year, primarily due to improved profitability and cash collections.

Looking ahead, Artivion remains optimistic about its growth trajectory, citing ongoing investments in research and development, particularly for regulatory approvals of new products. The company anticipates that its strategic initiatives, including the Endospan acquisition and continued expansion in international markets, will further bolster its market position. However, management also acknowledged potential risks related to market conditions, regulatory changes, and foreign currency fluctuations that could impact future performance.